Test drug INBRX-109 for advanced or metastatic solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child or adult who fits the age limits: at least 12 for Ewing sarcoma, or at least 18 for other solid tumors (and under 85).
- Your cancer type must be one of the study groups (Ewing sarcoma with a specific gene fusion, or colorectal cancer with specific prior treatment history).
- Your doctors must be able to measure your tumors on scans (measurable disease).
- You must be able to do treatment with good enough blood counts and organ function (kidneys, liver, and clotting) and have enough time left (at least 12 weeks).
- Your overall strength matters: performance status should be good (ECOG 0–1, or Karnofsky/Lansky 60+).
- You must provide tumor tissue—either old stored biopsy tissue or a new biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
This study tests an experimental drug, BR113, for people whose cancer has spread and not responded to standard treatments. It may offer a new option for those with advanced solid tumors, and the trial helps determine if the drug is safe and effective.
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.